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The purpose of writing this review on pulsatile drug delivery systems 
(PDDS) is to compile the recent literatures with special focus on the different 
types and approaches involved in the development of the formulation. PDDS 
are gaining importance in the field of pharmaceutical technology as these 
systems deliver the right dose at specific time at a specific site. Some of the 
disease conditions wherein PDDS are promising include duodenal ulcer, 
cardiovascular diseases, arthritis, asthma, diabetes, neurological disorder, 
cancer, hypertension and hypercholesterolemia. PDDS can be classified into 
time controlled systems wherein the drug release is controlled primarily by 
the delivery system, stimuli induced PDDS in which release is controlled by 
the stimuli, such as the pH or enzymes present in the intestinal tract or 
enzymes present in the drug delivery system and externally regulated system 
where release is programmed by external stimuli like magnetism, ultrasound, 
electrical effect and irradiation. This review also summarizes some current 
PDDS already available in the market. These systems are useful to several 
problems encountered during the development of a pharmaceutical dosage 
form. 
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Controlled drug delivery systems have acquired very 
important role in pharmaceutical Research and 
Development (R&D) business. Such systems offer 
control over the release of drug and grant a new lease 
on life to a drug molecule in terms of patentability. 
These dosage forms offer many advantages over the 
conventional drug delivery systems; such advantages 
include nearly constant drug level at the site of action, 
prevention of peak-valley fluctuations, reduction in 
dose of drug, reduced dosage frequency, avoidance of 
side effects, and improved patient compliance [1]. The 
oral controlled-release system shows a typical pattern  
 
of drug release in which the drug concentration is 
maintained in the therapeutic window for a prolonged 
period of time, thereby ensuring sustained therapeutic 
action.  
However, there are certain conditions for which such 
a release pattern is not suitable. These conditions 
demand release of drug after a lag time. In other 
words, it is required that the drug should not be 
released at all during the initial phase of dosage form 
administration. Such a release pattern is known as 
pulsatile release [2].  Recent studies have revealed 
that  diseases  have  a  predictable  cyclic  rhythm and  
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that the timing of medication regimens can improve 
the outcome of a desired effect [2]. This condition 
demands release of drug as a "pulse" after a time lag 
and such system has to be designed in a way that 
complete and rapid drug release should follow the lag 
time. Such systems are known as pulsatile drug 
delivery systems (PDDS), time-controlled systems, or 
sigmoidal release systems (Fig 1).   PDDS have been 
developed in close connection with emerging 
chronotherapeutic views. In this respect, it is well 
established that the symptoms of many pathologies, 
as well as the pharmacokinetic and pharmacodynamic 
profiles of most drugs, are subject to circadian 




Figure 1.  Schematic representation of different 
drug delivery systems where (a)= sigmoidal release 
after lag time, (b)= delayed release after lag time, 
(c) = sustained release after lag time, (d) = 
extended release without lag time. 
 
As far as widespread chronic pathologies with night 
or early morning symptoms are concerned, such as 
cardiovascular disease (CVD), bronchial asthma and 
rheumatoid arthritis, remarkable efficacy, tolerability 
and compliance benefits could arise from modified 
release medications. After bedtime administration, 
would allow the onset of therapeutic drug 
concentrations to coincide with the time at which 
disease manifestations are more likely to occur.  
Performance of pulsatile delivery fulfils such goals. 
In addition to being potentially suitable for 
chronotherapy, pulsatile release is also exploited to 
target proximal as well as distal colonic regions via 
the oral route. Colon delivery is being extensively 
investigated as it may yield improved topical 
inflammatory bowel disease (IBD) treatments and is 
even suggested as one means of enhancing the poor 
oral bioavailability of peptides, proteins, 
oligonucleotides and nucleic acids. For the purpose of 
time-controlled colon targeting, delayed-release 
systems have to be presented in an enteric-coated 
configuration so that the high intra- and inter-subject 
variability in gastric residence may be overcome, and 
provide, following stomach emptying, a lag phase 
roughly corresponding to fairly reproducible small 
intestinal transit time [3]. 
 
Diseases targeted for pulsatile technology 
 Diseases presently targeted for chronopharmaceutical 
formulations are those for which there are enough 
scientific backgrounds to justify PDDS- compared to 
the conventional drug administration approach. They 
include: hypercholesterolemia, asthma, cancer, 
duodenal ulcer, arthritis, diabetes, neurological 
disorders, cardiovascular diseases (e.g. hypertension 
and acute myocardial infarction) and colonic delivery. 
The rationale for chronotherapy/pulsatile release for 




Diverse directions of circadian changes in lipid 
fractions in patients and normal subjects may 
contribute to alteration in the rhythmicity of other 
metabolisms and in the blood coagulation system, 
thus leading to various complications [8]. A circadian 
rhythm occurs during hepatic cholesterol synthesis [9, 
10]. Therefore, cholesterol synthesis is generally 
higher during the night than during daylight,. The 
maximal production occurs early in the morning, i.e. 
12 h after the last meal [11]. Studies with HMG CoA 
reductase inhibitors have suggested that evening 




The chronotherapy of asthma has been extensively 
studied. The role of circadian rhythms in the 
pathogenesis and treatment of asthma indicates that 
airway resistance increases progressively at night in 
asthmatic patients [14]. Circadian changes are seen in 
normal lung function, which reaches a low point in 
the early morning hours. As broncho constriction and 
exacerbation of symptoms vary in a circadian fashion, 
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asthma is well suited for chronotherapy. 
Chronotherapies have been studied for asthma with 




Human and animal studies suggest that chemotherapy 
may be more effective and less toxic if cancer drugs 
are administered at carefully selected times that take 
advantage of tumor cell cycles while less toxic to 
normal tissue [17, 18] .The blood flow to tumors  was 
threefold greater during each daily activity phase of 
the circadian cycle than during the daily rest phase 
[19]. The chronotherapy concept offers further 
promise for improving current cancer-treatment 
options, as well as for optimizing the development of 
new anticancer or supportive agents [20]. 
 
iv. Duodenal ulcer 
Many of the functions of the gastrointestinal tract are 
subject to circadian rhythms: gastric acid secretion is 
highest at night [21, 22], while gastric and small 
bowel motility and gastric emptying are all slower at 
night. During night time, when gastric motility and 
emptying are slower, drug disintegration, dissolution, 
and absorption may be slower [23]. In peptic ulcer 
patients, gastric acid secretion is highest during the 
night. Suppression of nocturnal acid is an important 
factor in duodenal ulcer healing. Therefore, for active 
duodenal ulcer, once daily at bedtime is the 




The chronobiology, chronopharmacology and 
chronotherapeutics of pain have been extensively 
reviewed [25]. For instance, there is a circadian 
rhythm in the plasma concentration of C - reactive 
protein [26] and interleukin-6 [27] of patients with 
rheumatoid arthritis. Patients with osteoarthritis tend 
to have less pain in the morning and more at night; 
while those with rheumatoid arthritis, have pain that 
usually peaks in the morning and decreases 
throughout the day. Chronotherapy for all forms of 
arthritis using NSAIDs such as Ibuprofen should be 
timed to ensure that the highest blood levels of the 
drug coincide with peak pain.  
vi. Diabetes 
The circadian variations of glucose and insulin in 
diabetes have been extensively studied and their 
clinical importance in case of insulin substitution in 
type I diabetes have been previously discussed [28, 
29]. The goal of insulin therapy is to mimic the 
normal physiologic pattern of endogenous insulin 
secretion in healthy individuals, with continuous basal 
secretion as well as meal-stimulated secretion.  
 
vii. Neurological disorders 
As an integrative discipline in physiology and 
medical research, chronobiology renders the 
discovery of new regulation processes regarding the 
central mechanisms of epilepsy. Chronophysiology 
investigations considered at a rhythmometric level of 
resolution suggest several heuristic perspectives 
regarding (i), the central pathophysiology of epilepsy 
and (ii) the behavioural classification of convulsive 
events [30]. 
 
viii. Cardiovascular diseases 
Several functions such as. Blood pressure (BP), heart 
rate, stroke volume, cardiac output, blood flow of the 
cardiovascular system are subject to circadian 
rhythms. For instance, capillary resistance and 
vascular reactivity are higher in the morning and 
decrease later in the day. Platelet aggregability is 
increased and fibrinolytic activity is decreased in the 
morning, leading to a state of relative 
hypercoagulability of the blood [31, 32]. It was 
postulated that modification of these circadian 
triggers by pharmacologic agents may lead to the 
prevention of adverse cardiac events [33]. BP is at its 
lowest during the sleeping period and rises steeply 
during the early morning period. Most patients with 
essential hypertension have a similar circadian 
rhythm of BP as do normotensive persons, although 
hypertensive patients have an upward shift in the 
profile [34].  
 
ix. Colonic delivery 
The colon is also seen as the preferedabsorption site 
for oral administration of protein and peptide drugs, 
because of the relatively low proteolytic enzyme 
activities in the colon. A colon-specific drug delivery 
system should prevent drug release in the stomach 
and small intestine, and affect an abrupt onset of drug 
release upon entry into the colon. Time dependent 
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delivery has also been proposed as a means of 
targeting the colon. Time-dependent systems release 
their drug load after a pre-programmed time delay. To 
attain colonic release, the lag time should equate to 
the time taken for the system to reach the colon. This 
time is difficult to predict in advance, although a time 
lag of five hours is usually considered sufficient, 
given that small intestinal transit time is reported to 
be relatively constant at three to four hours [35]. 
All of these conditions demand a time-programmed 
therapeutic scheme releasing the correct amount of 
dose of the drug at the appropriate time. This 
requirement is usually fulfilled by PDDS.  
 
Methodologies for PDDS  
Methodologies  for   the   PDDS   can   be    broadly  
 
classified into four classes; 
 
I. Time controlled pulsatile release  
A. Single unit system   
B. Multi-particulate system 
II. Stimuli induced 
A. Thermo-Responsive Pulsatile release 
B. Chemical stimuli induced Pulsatile 
systems 
III. External stimuli pulsatile release  
A. Electro responsive pulsatile release 
B. Magnetically induced pulsatile release 
IV. Pulsatile release systems for vaccine and 
hormone products 
 
I. Time controlled pulsatile release system 
These time-controlled systems can be classified as 
single unit (e.g., tablet or capsule) or multiple unit 
systems.  
 
1. Single unit systems 
i. Capsular Systems  
Different single-unit capsular PDDS have been 
developed (Fig 2). A general -design of such systems 
consists of an insoluble capsule body housing a drug 
and a plug. The plug is removed after a predetermined 
time lag due to swelling, erosion, or dissolution.  The 
Pulsincap® system is an example of such a system 
that is made up of a water-insoluble capsule body 
filled with drug formulation [36]. The body is closed 
at the open end with a swellable hydrogel plug. Upon 
contact with dissolution medium or gastro-intestinal 
fluids, the plug swells, pushing itself out of the 
capsule after a time lag. This is followed by a 
spontaneous release of the drug (Fig 2). The time lag 
can be controlled by manipulating the dimension and 
the position of the plug. For water insoluble drugs, a 
spontaneous release can be ensured by inclusion of 
effervescent agents or disintegrants. The plug material 
consists of insoluble but permeable and swellable 
polymers (e.g.:polymethacrylates) [37,38], erodible 
compressed polymers (e.g: hydroxypropylmethyl 
cellulose, polyvinyl alcohol, polyethylene oxide), 
congealed melted polymers (e.g: saturated 
polyglycolated glycerides, glycerylmonoole and 
enzymatically controlled erodible polymer  
e.g:pectin). These formulations are well tolerated in 
animals and healthy volunteers, and there have been 
no reports of gastro-intestinal irritation. However, 
there was a potential problem of variable gastric 
residence time, which was overcome by enteric 
coating the system to allow its dissolution only in the 
higher pH region of small intestine. 
 
ii.Port systems 
The Port System - consists of a gelatin capsule coated 
with a semi permeable membrane (e.g: cellulose 
acetate) housing an insoluble plug ( e.g: lipidic) and 
an osmotically active agent along with the drug 
formulation [39]. When it comes in contact with the 
aqueous medium, water diffuses across the semi 
permeable membrane, resulting in increased inner 
pressure that ejects the plug after a – time lag. The 
time lag is controlled by the thickness of semi 
permeable membrane. The system showed good 
correlation in lag times of in-vitro and in-vivo 
experiments in humans [40]. 
In order to deliver drug in liquid form, an osmotically 
driven capsular system was developed. In this system, 
liquid drug is absorbed into highly porous particles, 
which release the drug through an orifice of a semi 
permeable capsule supported by an expanding 
osmotic layer after the barrier layer is dissolved [41]. 
The capsular system delivers drug by the capsule's 
osmotic infusion of moisture from the body. The 
capsule wall is made up of an elastic material and 
possesses an orifice. As the osmosis proceeds, the 
pressure within the capsule rises, causing the wall to 
stretch. The orifice is small enough so that when the 
elastic wall relaxes, the flow of the drug through the 
orifice  essentially  stops,  but when the elastic wall is  
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distended beyond threshold value, the orifice expands  
sufficiently to allow drug release at a required rate. 
Elastomers, such as styrene-butadiene copolymer 





Figure 2. Schematic diagram of capsular system. 
 
 
iii.Delivery by a series of stops 
This system is described for implantable capsules. 
The capsule contains a drug and a water-absorptive 
osmotic engine that are placed in compartments 
separated by a movable partition. The pulsatile 
delivery is achieved by a series of stops along the 
inner wall of the capsule. These stops obstruct the 
movement of the partition but are overcome in 
succession as the osmotic pressure rises above a 
threshold level. The number of stops and the 
longitudinal placements of the stops along the length 
of the capsule dictate the number and frequency of the 
pulses, and the configuration of the partition controls 
the pulse intensity. This system was used to deliver 
porcine somatotropin [44]. 
 
iv.Delivery by solubility modulation  
These systems contain a solubility modulator for 
pulsed delivery of variety of drugs. The system was 
especially developed for delivery of salbutamol 
sulphate [45]. The compositions contain the drug 
(salbutamol sulphate) and a modulating agent, sodium 
chloride (NaCl). The amount of NaCl was such that it 
was less than the amount needed to maintain 
saturation in a fluid that enters the osmotic device. 
The pulsed delivery is based on drug solubility. 
Salbutamol has solubility of 275 mg/ml in water and 
16 mg/ml in saturated solution of NaCl, while NaCl 
has solubility of 321 mg/ml in water, and its 
saturation solubility is 320 mg/ml. These values show 
that the solubility of the drug is a function of the 
modulator concentration, while the modulators 
solubility is largely independent of drug 
concentration. The modulating agent can be a solid 
organic acid, inorganic salt, or organic salt. 
 
v. Delivery by reservoir systems with erodible or 
soluble barrier coatings  
Most of the pulsatile drug delivery systems are 
reservoir devices coated with a barrier layer. This 
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barrier erodes or dissolves after a specific lag period, 
and the drug is subsequently released rapidly. The 
time lag depends on the thickness of the coating layer 
[46].  
The Time Clock® system consists of a solid dosage 
form coated with lipid barriers containing carnauba 
wax and bees wax along with surfactants, such as 
polyoxyethylene sorbitan monooleate [47, 48]. This 
coat erodes or emulsifies in the aqueous environment 
in a time proportional to the thickness of the film, and 
the core is then available for dispersion. The major 
advantage of this system is its ease of manufacture 
without any need of special equipment. The 
disadvantage of this system is a premature drug 
release when the penetrating water dissolves the drug.  
The Chronotropic® system consists of a drug-
containing core coated by hydrophilic swellable 
hydroxypropylmethyl cellulose (HPMC), which is 
responsible for a lag phase in the onset of drug release 
[49]. Time lag is controlled by the thickness and the 
viscosity grades of HPMC used in coating the drug 
core. The system is suitable for both tablets and 
capsule formulations [50].   
 
2. Multiparticulate Systems  
Multi-particulate drug delivery systems are mainly 
oral dosage forms consisting of a multiplicity of small 
discrete units, in which the active substance is present 
as a number of small independent subunits. They 
provide many advantages over single-unit systems 
because of their small size, less inter and intra-subject 
variability in gastrointestinal transit time, reduced 
adverse effects and improved tolerability, no risk of 
dose dumping, flexibility in design and finally 
Improve stability However, there are some draw 
backs in this system, which include lack of 
manufacturing reproducibility, high cost of 
production, multiple formulation steps and also the 
need of advanceed technologies. 
There are different types of multiparticulate systems 
and these are enumerated and explained below: 
1. Pulsatile System Based on Rupturable Coating  
This is a multiparticulate system in which drug is 
coated on non-pareil sugar seeds followed by a 
swellable layer and an insoluble top layer [51, 52]. 
The swelling agents used include superdisintegrants 
like sodium carboxymethyl cellulose, sodium starch 
glycollate, L-hydroxypropyl cellulose, etc. Upon 
ingress of water, the swellable layer expands, 
resulting in rupture of film with subsequent rapid 
drug release. The release is independent of 
environmental factors like pH and drug solubility. 
The lag time can be varied by varying coating 
thickness or adding high amounts of lipophilic 
plasticizer in the outermost layer. 
 
2. Time controlled expulsion system 
This system is based on a combination of osmotic and 
swelling effects. The core contains the drug, a low 
bulk density solid and/or liquid lipid material (e.g., 
mineral oil) and a disintegrant. The core is further 
coated with cellulose acetate. Upon immersion in 
aqueous medium, water penetrates the core displacing 
the lipid material. After the depletion of lipid 
material, internal pressure increases until a critical 
stress is reached, which results in rupture of the 
coating material [53]. Another system is based on a 
capsule or tablet composed of a large number of 
pellets consisting of two or more pellets or part [54].  
 
3. Pulsatile Delivery by Change in Membrane 
Permeability 
The permeability and water uptake of acrylic 
polymers with quaternary ammonium groups can be 
influenced by the presence of different counter-ions in 
the medium [55]. Several delivery systems based on 
this ion exchange have been developed. Eudragit RS 
30D is reported to be a polymer of choice for this 
purpose [56]. It typically contains positively polarized 
quaternary ammonium group in the polymer side 
chain, which is always accompanied by negative 
hydrochloride counter-ions. The ammonium group 
being hydrophilic it facilitates the interaction of 
polymer with water, thereby changing its permeability 
and allowing water to permeate the active core in a 
controlled manner. 
 
4. Sigmoidal Release System 
This consists of pellet cores comprising drug and 
succinic acid coated with ammonio-methacrylate 
copolymer USP/NF type B. The time lag is controlled 
by the rate of water influx through the polymer 
membrane. The water dissolves acid and the drug in 
the core. The acid solution in turn increases 
permeability of the hydrated polymer film. The 
different types of acids that can be used include 
succinic acid, acetic acid, glutaric acid, tartaric acid, 
malic acid, or citric acid [57, 58].  
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5. Low density floating multiparticulate pulsatile 
systems 
Conventional multiparticulate pulsatile release dosage 
forms mentioned above are having longer residence 
time in the gastrointestinal tract and due to highly 
variable nature of gastric emptying process may result 
in in vivo variability and bioavailability problems. In 
contrary, low density floating multiparticulate 
pulsatile dosage forms reside only in stomach and not 
affected by variability of pH, local environment or 
gastric emptying rate. These dosage forms are also 
specifically advantageous for drugs either absorbed 
from the stomach or requiring local delivery in 
stomach [59].  
 
II. Stimuli induced pulsatile release system 
Several polymeric delivery systems undergo phase 
transitions and demonstrate marked swelling-
deswelling changes in response to environmental 
changes including solvent composition, ionic 
strength, temperature, electric fields, and light [60]. 
Responsive drug release from those systems results 
from the stimuli-induced changes in the gels or in the 
micelles, which may deswell, swell, or erode in 
response to the respective stimuli. The mechanisms of 
drug release include ejection of the drug from the gel 
as the fluid phase synerges out, drug diffusion along a 
concentration gradient, electrophoresis of charged 
drugs towards an oppositely charged electrode and 
liberation of the entrapped drug as the gel or micelle 
complex erodes [61]. 
 
Chemical stimuli induced pulsatile systems 
i. Glucose-responsive insulin release devices 
In case of Diabetes mellitus there is rhythmic increase 
in the levels of glucose in the body, requiring 
injection of the insulin at proper time. Several 
systems have been developed which are able to 
respond to changes in glucose concentration. One 
such system includes pH sensitive hydrogel 
containing glucose oxidase immobilized in the 
hydrogel. When glucose concentration in the blood 
increases glucose oxidase converts glucose into 
gluconic acid which changes the pH of the system. 
This pH change induces swelling of the polymer 
which results in insulin release. Insulin by virtue of its 
action reduces blood glucose level and consequently 
gluconic acid level also gets decreased and system 
turns to the deswelling mode thereby decreasing the 
insulin release. Examples of the pH sensitive 
polymers include N, N-dimethylaminoethyl 
methacrylate, chitosan, polyol etc [62, 63]. 
  
ii. Inflammation-induced pulsatile release 
On receiving any physical or chemical stress, such as 
injury, fracture etc., inflammation take place at the 
injured sites. During inflammation, hydroxyl radicals 
are produced from these inflammation-responsive 
cells. Degradation via hydroxyl radicals however, is 
usually dominant and rapid when   Hyaluronic Acid 
gel is injected at inflammatory sites. Thus, it is 
possible to treat patients with inflammatory diseases 
like rheumatoid arthritis; using anti-inflammatory 
drug incorporated HA gels as new implantable drug 
delivery systems [64]. 
 
iii.  Drug release from intelligent gels responding to 
antibody concentration 
There are numerous kinds of bioactive compounds 
which exist in the body. Recently, novel gels were 
developed which responded to the change in 
concentration of bioactive compounds to alter their 
swelling/deswelling characteristics. Special attention 
was given to antigen-antibody complex formation as 
the cross-linking units in the gel, since such 
interaction is very specific. Utilizing the difference in 
association constants between polymerized antibodies 
and naturally derived antibodies towards specific 
antigens, reversible gel swelling/deswelling and drug 
permeation changes occurs. 
 
iv. pH sensitive drug delivery system 
This type of PDDS contains two components. The 
first is fast release type while the other is pulsed 
release which releases the drug in response to change 
in pH. In case of pH dependent system, advantage has 
been taken of the fact that there exists different pH 
environment at different parts of the gastrointestinal 
tract. By selecting the pH dependent polymers drug 
release at specific location can be obtained. Examples 
of pH dependent polymers include cellulose acetate 
phthalate, polyacrylates, and sodium 
carboxymethylcellulose. These polymers are used as 
enteric coating materials so as to provide release of 
drug in the small intestine [65].  
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  III. External stimuli pulsatile release:  
This system was divided into three subparts and is 
discussed below. 
1. Electro responsive pulsatile release  
Electrically responsive delivery systems are prepared 
from polyelectrolytes (polymers which contain 
relatively high concentration of ionisable groups 
along the backbone chain) and are thus, pH-
responsive as well as electro-responsive. Examples of 
naturally occurring polymers include hyaluronic acid, 
chondroitin sulphate, agarose, carbomer, xanthan gum 
and calcium alginate. The synthetic polymers are 
generally acrylate and methacrylate derivatives such 
as partially hydrolyzed polyacrylamide, 
polydimethylaminopropyl acrylamide [66]. 
 
2. Micro electro mechanical systems (MEMS)    
A micro fabricated device has the ability to store and 
release multiple chemical substances on demand by a 
mechanism devoid of moving its parts [66, 67]. The 
digital capabilities of MEMS may allow greater 
temporal control over drug release compared to 
traditional polymer-based systems.  Another 
development in MEMS technology is the microchip. 
The microchip consists of an array of reservoirs that 
extend through an electrolyte-impermeable substrate. 
The prototype microchip is made of silicon and 
contains a number of drug reservoirs, each reservoir is 
sealed at one end by a thin gold membrane of material 
that serves as an anode in an electrochemical reaction 
and dissolves when an electric potential is applied to 
it in an electrolyte solution. The reservoirs are filled 
with any combination of drug or drug mixtures in any 
form (i.e. solid, liquid or gel). When release is 
desired, an electric potential is applied between an 
anode membrane and a cathode, the gold membrane 
anode dissolves within 10-20 seconds and allows the 
drug in the reservoir to be released. This electric 
potential causes oxidation of the anode material to 
form a soluble complex with the electrolytes which 
then dissolves allowing release of the drug. Complex 
release patterns (such as simultaneous constant and 
pulsatile release) can be achieved from the 
microchips. Microchip has the ability to control both 
release time and release rate. 
3. Magnetically induced pulsatile release 
The use of an oscillating magnetic field to modulate 
the rates of drug release from polymer matrix was one 
of the old methodologies. Magnetic carriers receive 
their magnetic response to a magnetic field from 
incorporated materials such as Magnetite, Iron, 
Nickel, Cobalt etc. For biomedical applications, 
magnetic carriers must be water-based, 
biocompatible, non-toxic and non-immunogenic 
mechanistic approach based on magnetic attraction is 
the slowing down of oral drugs in the gastrointestinal 
system. This is possible by filling an additional 
magnetic component into capsules or tablets. The 
speed of travel through the stomach and intestines can 
then be slowed down at specific positions by an 
external magnet, thus changing the timing and/ or 
extent of drug absorption into stomach or intestines 
[68]. 
 
IV. Pulsatile release systems for vaccine and 
hormone products   
Vaccines are traditionally administered as an initial 
shot of an antigen followed by repeated booster shots 
to produce protective immunity [69]. The frequency 
of the booster shots, and hence the exact 
immunisation- schedule is antigen dependent. Also, 
co-administration of vaccine adjuvant is often 
required to enhance the immune response to achieve 
protective immunity [70]. PDDS offer the possibility 
of single-shot vaccines if initial booster release of the 
antigen can be achieved from one system in which 
timing of booster release is controlled. Vizcarra et al. 
found in nutritionally anoestrous cows, GnRH 
administered in pulses of 2 mg over 5 min every hour 
for 13 days produced a higher frequency of luteal 
activity by 13th day than cows given continuous 
infusions or pulses every 4 Hr. 
 
Recent Techniques of Oral Time Controlled 
Pulsatile Technology 
Currently, pharmaceutical companies have been 
focused on developing and commercializing PDDS 
that fulfil unmet medical needs in the treatment of 
various diseases. Recently developed technologies are 
SODAS® Technology, IPDAS® Technology, 
CODAS™ Technology, GEOCLOCK® Technology, 
PULSYS™ Technology, Eurand’s pulsatile and 
Chrono Release System, Magnetic Nanocomposite 
Hydrogel.  
 
Spheroidal Oral Drug Absorption System 
(SODAS) 
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This technology is based on the production of 
controlled release beads and it is characterized by its 
inherent flexibility, enabling the production of 
customized dosage forms that respond directly to 
individual drug candidate needs. SODAS can provide 
a number of tailored drug release profiles, including 
immediate release of drug followed by sustained 
release to give rise to a fast onset of action, which is 
maintained for 24 hours.  However, the opposite 
scenario can be achieved where drug release is 
delayed for a number of hours. An additional option 
is pulsatile release, where a once daily dosage form 
can resemble multiple daily doses by releasing drug 
in discrete bursts throughout the day [71].  
 
The Intestinal Protective Drug Absorption System 
(IPDAS)  
This Technology is a high density multiparticulate 
tablet technology, intended for gastrointestinal irritant 
compounds. The IPDAS® technology is composed of 
numerous high density controlled release beads, 
which are compressed into a tablet form. Once an 
IPDAS® tablet is ingested, it rapidly disintegrates 
and disperses beads containing a drug in the stomach, 
which subsequently pass into the duodenum and 
along the gastrointestinal tract in a controlled and 
gradual manner, independent of the feeding state. 
Release of active ingredient from the 
multiparticulates occurs through a process of 
diffusion either through the polymeric membrane and 
or the micro matrix of polymer/active ingredient 
formed in the extruded/spheronized multiparticulates. 
The intestinal protection of IPDAS® technology is by 
virtue of the multiparticulate nature of the 
formulation, which ensures wide dispersion of irritant 
drug throughout the gastrointestinal tract. Naprelan®, 
which is marketed in the United States and Canada, 
employs the IPDAS® technology. This innovative 
formulation of naproxen sodium is a novel controlled 
release formulation indicated for the treatment of 
acute and chronic pain. 
 
Chronotherapeutic Oral Drug Absorption System 
(CODAS) 
This technology was designed to release its drug 
component after a prolonged period of time when 
administered. A good example is Verelan® PM, 
which was designed to release Verapamil 
approximately four to five hours after ingestion. This 
delay is introduced by the level of release-controlling 
polymer applied to the drug-loaded beads .The 
release-controlling polymer is a combination of 
water-soluble and water-insoluble polymers.  When 
fluid from the gastrointestinal tract contacts the 
polymer coat beads, the water-soluble polymer slowly 
dissolves, and the drug diffuses through the resulting 
pores in the coating. The water-insoluble polymer 
continues to act as a barrier, maintaining the 
controlled-release of the drug. When taken at 
bedtime, this controlled onset extended release 
delivery system enables a maximum plasma 
concentration of Verapamil in the morning hours, 
when blood pressure normally is high [72]. 
 
GEOCLOCK® Technology 
Geoclock® tablets have an active drug inside an outer 
tablet layer consisting of a mixture of hydrophobic 
wax and brittle material in order to obtain a pH-
independent lag time prior to core drug delivery at a 
predetermined release rate. This dry coating approach 
is designed to allow the timed release of both slow 
release and fast release active cores by releasing the 
inner tablet first after which the surrounding outer 
shell gradually disintegrates.  SkyePharma has used 
this novel technology to develope Lodotra™, a 
rheumatoid arthritis drug, which delivers the active 
pharmaceutical ingredient at the most suitable time of 
day to treat the disease condition [73]. 
 
PULSYS™ Technology  
This is an oral drug delivery technology that enables 
once daily pulsatile dosing.  The PULSYS™ dosage 
form is a compressed tablet that contains pellets 
designed to release drug at different regions in the 
gastro-intestinal tract in a pulsatile manner. The 
dosage form is made up of multiple pellet types of 
varying release profiles that are combined in a 
proportion so as to produce a constant escalation in 
plasma drug levels in the early portion of the dosing 
interval. The transit properties of pellets enhance the 
overall absorption-time window and offer improved 
bioavailability compared to tablet matrix forms. 
  
EURANDs pulsatile and chrono release System 
This system is capable of providing one or more rapid 
release pulses at predetermined times lag. They can 
Sharma et al. International Journal of Drug Delivery 2 (2010) 200-212 
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help to optimize efficacy and/or minimize side-effects 
of a drug substance. For example, Eurand has created 
a circadian rhythm release (CRR) dosage form for a 
cardiovascular drug, Propranolol hydrochloride, with 
a four-hour delay in release after oral administration. 
When administered at bedtime, Propranolol is 
released after the initial delay such that maximum 
plasma level occurs in the early morning hours, when 
the patient is mostly at risk [74]. 
 
Magnetic Nanocomposite Hydrogel  
Magnetic nanocomposite was synthesized by 
incorporation of super paramagnetic Ferric oxide 
particles in temperature sensitive poly (N-
isopropylacrylamide) hydrogels. High frequency 
alternating magnetic field was applied to produce 
pulsatile drug release from nanocomposite hydrogel. 
Nanocomposites hydrogel are one type of On--Off 
device where drug release can be turn on by 
application of alternative magnetic field [75]. 
 
Futuristic Prospect Of PDDS 
The development of pulsatile-release products is very 
challenging since it requires the correct dose to reach 
the right site at the appropriate time. Multiparticulate 
PDDS offer more advantages when compared with 
the single-unit pulsatile systems since it has 
predictable, reproducible and short gastric empty time 
with no risk of dose dumping. However, the novel 
PDDS pays more attention on site and time-
specificity. It is believed that in the near future novel 
PDDS will be explored in the treatment or 




Presently, oral delivery of drug is still by far the most 
preferable route of drug delivery due to the ease of 
administration, patient compliance and flexibility in 
its formulations. Generally, sustained and controlled-
release products provide a desired therapeutic effect, 
but fall short of diseases following biological 
rhythms. Circadian disorders such as hypertension, 
osteoarthritis, asthma etc., which require 
chronopharmacotherapy. PDDS can effectively tackle 
this problem as it is modulated according to body's 
circadian clock giving release of drug after a specified 
time lag. However, for the last two decades, 
technologies to ensure time-controlled pulsatile 
release of bioactive compounds have been developed. 
A significant progress has been made toward 
achieving PDDS that can effectively treat diseases 
with non-constant dosing therapies. Various pulsatile 
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